Eltrombopag in Pediatric Severe Aplastic Anemia: Favorable Outcomes
Blood Journals Portfolio shared a post on X:
”Eltrombopag’s pharmacokinetics profile was similar to that seen in patients with immune thrombocytopenia, with no unexpected safety signals.”
Read the full article here.
Title: Eltrombopag in combination with immunosuppressive therapy in pediatric severe aplastic anemia: phase 2 ESCALATE trial
Authors: Akiko Shimamura, Alexey Maschan, Carolyn Bennett, Sujith Samarasinghe, Jason E. Farrar, Chi-kong Li, Nongnuch Sirachainan, Bunchoo Pongtanakul, Patcharee Komvilaisak, Ludmila Zubarovskaya, Jennifer A. Rothman, Kelly Walkovich, Taizo A. Nakano, Alison A. Bertuch, Anabela Ferrao, Rukhmi Bhat, Rabi Hanna, Kathleen Overholt, Jessica Boklan, Tze Fang Wong, Qinxia Wang, Patrick Urban, Brigitte Strahm, Winfred Wang, Adrianna Vlachos, David A. Williams
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Nov 27, 2025, 16:00Nathan Connell on WFH AI Summaries from the Global Forum
-
Nov 27, 2025, 15:49Piotr Czempik: Rethinking Coagulation in Acute Liver Dysfunction
-
Nov 27, 2025, 15:35Overwhelmed? A Leader’s Guide from Mark Crowther to Getting Back on Track
-
Nov 27, 2025, 15:10Wolfgang Miesbach’s Top 10 Picks for TTP and Thrombosis from ASH 2025
-
Nov 27, 2025, 14:24ICCBBA’s Executive Director Eoin McGrath Chairs a Dynamic Session on AI, Innovation and Informatics in Transfusion Medicine
-
Nov 27, 2025, 13:26Wolfgang Miesbach’s Top 10 Picks for Bleeding Disorders from ASH 2025
-
Nov 27, 2025, 11:19Priya Prasad Presents a Case of Severe Hypotensive Transfusion Reaction
-
Nov 27, 2025, 04:07Eugene Tang Presents Highlights from UK Stroke Forum 2025
-
Nov 27, 2025, 03:47Michael Makris: I Believe the Time Has Come to Consider Emicizumab Up Front in Persons with Acquired Hemophilia